8-K: AirSculpt Q3 Revenue Misses, CFO Appointed

AirSculpt Technologies reported a significant decline in third-quarter revenue and net loss, lowered its full-year guidance, and announced the appointment of Michael Arthur as its new Chief Financial Officer.

Summary

• AirSculpt Technologies reported third-quarter 2025 revenue of $35.0 million, a 17.8% decrease from $42.5 million in Q3 2024.
• The company posted a net loss of $9.5 million for Q3 2025, compared to a net loss of $6.0 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $3.0 million, down from $4.7 million in Q3 2024.
• For the first nine months of 2025, revenue declined 16.1% to $118.4 million, and net loss increased to $13.0 million from $3.2 million in the prior year period.
• Full-year 2025 revenue guidance was updated to approximately $153 million, down from the previous range of $160 million to $170 million.
• Full-year 2025 Adjusted EBITDA guidance was adjusted to approximately $16 million, at the lower bound of the previous range.
• Michael Arthur has been hired as the new Chief Financial Officer, effective January 5, 2026, with an annual base salary of $400,000 and a comprehensive equity and cash bonus package.
• The company reduced debt by $18 million and generated $5.6 million in operating cash flow year-to-date, maintaining compliance with bank covenants.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in revenue, net income, and Adjusted EBITDA, coupled with a lowered full-year guidance. These financial underperformances are substantial. However, the appointment of a new CFO, the strategic focus on adapting to the GLP-1 market, and reported improvements in Q4 same-store sales trends offer some mitigating positive outlook for future quarters, preventing a severely negative score.

Positives

• The company completed its financing in Q2 and reduced debt by $18 million, strengthening its balance sheet.
• Generated positive operating cash flow of $5.6 million for the first nine months of 2025.
• Maintained compliance with bank covenants as of September 30, 2025.
• Appointed Michael Arthur as Chief Financial Officer, a seasoned executive with public market experience, expected to add meaningfully to the leadership team.
• Management sees a broader market opportunity driven by the structural shift in the aesthetics space due to GLP-1 use and is shaping its strategy to capitalize on this potential.
• Experiencing an improvement in same-store sales trends as of the fourth quarter.
• Expects expense discipline to result in year-over-year EBITDA margin expansion in Q4.

Negatives

• Third-quarter 2025 revenue declined 17.8% to $35.0 million, lower than anticipated.
• Net loss for Q3 2025 increased to $9.5 million from $6.0 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 decreased to $3.0 million from $4.7 million in Q3 2024.
• Case volume for Q3 2025 declined 15.2% to 2,780 cases.
• Full-year 2025 revenue guidance was lowered to approximately $153 million from a previous range of $160 million to $170 million.
• Full-year 2025 Adjusted EBITDA guidance was adjusted to the lower bound of the previous range, at approximately $16 million.
• Same-center case volume declined by 20.5% in Q3 2025 and 22.5% for the first nine months of 2025.
• Recorded a $2.3 million loss related to the planned closure of the London facility and impairment of its fixed assets, and a $4.6 million loss related to impairing a portion of the Salesforce implementation project.

Risks

• Inability to sell equity or other securities in the future at a time when the company might otherwise wish to effect sales.
• Inability to raise capital on commercially reasonable terms, if at all.
• Risk that any future financings may dilute stockholders or restrict business operations.
• Failure to stabilize same-store performance.
• Not being able to optimize marketing investment, go-to-market strategy, and sales process.
• Not having the ability to expand financing options for consumers.
• Being unsuccessful in further product innovations.
• Failure to operate centers in a cost-effective manner.
• Increased operating expenses due to rising inflation.
• Increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability, and customer awareness of weight-loss drugs (GLP-1s).
• Shortages or quality control issues with third-party manufacturers or suppliers.
• Competition for surgeons.
• Litigation or medical malpractice claims.
• Inability to protect the confidentiality of proprietary information.
• Changes in the laws governing the corporate practice of medicine or fee-splitting.
• Changes in regulatory, macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where facilities are located.
• Business disruption or other losses from natural disasters, war, pandemic, terrorist acts, or political unrest.

Future Outlook

The company updated its full-year 2025 revenue guidance downwards to approximately $153 million and adjusted its full-year 2025 Adjusted EBITDA guidance to approximately $16 million, the lower bound of its previous range. Management anticipates a broader market opportunity driven by the structural shift in the aesthetics space due to GLP-1 use and is actively shaping its strategy to realize this potential. The company is experiencing an improvement in same-store sales trends as it enters the fourth quarter and expects expense discipline to lead to year-over-year EBITDA margin expansion.

Management Comments

• Yogi Jashnani, CEO, stated: 'During the quarter, we made strong progress on our key initiatives that focused on new growth opportunities, margin improvement, and debt reduction.'
• Jashnani noted: 'While third quarter revenue was lower than anticipated, this is reflective of timing, instead of the trajectory of our business.'
• Jashnani highlighted: 'We see a broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 use and we have begun to shape our strategy to realize this potential.'
• Jashnani added: 'As we enter the fourth quarter, we are experiencing an improvement in our same store sales trends and expect our expense discipline to result in EBITDA margin expansion year over year.'
• Jashnani emphasized: 'AirSculpt is scaled and trusted — strongly positioned at the intersection of aesthetics and the GLP-1.'
• Jashnani concluded: 'I remain confident in our strategy and our ability to deliver long term consistent revenue and profit growth and increased value for our shareholders.'
• Jashnani expressed pleasure: 'I am pleased to attract Michael Arthur to AirSculpt as Chief Financial Officer. He is a seasoned executive who brings public market experience and has led finance organizations through growth, complexity, and change. I'm confident he will add meaningfully to our leadership team. Michael starts January 5, 2026.'

Industry Context

The company acknowledges a 'structural shift in the aesthetics space due to GLP-1 use,' indicating a recognition of the growing impact of weight-loss drugs on the demand for body contouring procedures. AirSculpt aims to position itself at the 'intersection of aesthetics and the GLP-1,' suggesting a strategic pivot to adapt to evolving consumer needs and market dynamics influenced by these pharmaceutical advancements. This indicates a proactive approach to integrate or differentiate its services in a market potentially reshaped by non-surgical weight loss solutions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Negative impact from declining revenue, increased net losses, and lowered guidance, potentially affecting share price. However, the appointment of a new CFO and strategic pivot could offer long-term value creation.
• Employees: Change in key leadership with the appointment of a new CFO. The closure of the London facility may impact employees in that location.
• Customers: Potential for expanded financing options and product innovations, as mentioned in risk factors, could improve customer experience.
• Creditors: The company remains compliant with bank covenants and has reduced debt, which is positive for creditors, but declining financial performance could raise concerns if trends continue.

Next Steps

• Michael Arthur will commence his role as Chief Financial Officer on January 5, 2026.
• The company will continue to shape its strategy to capitalize on the broader market opportunity driven by GLP-1 use in the aesthetics space.
• Management expects expense discipline to result in year-over-year EBITDA margin expansion in the fourth quarter of 2025.
• The company will hold a conference call on November 7, 2025, to discuss the results.

Key Dates

Recommendation

The company's Q3 2025 results show significant underperformance with declining revenue, increased net losses, and a reduction in full-year guidance, which are strong negative indicators. However, the appointment of a new, experienced CFO and the stated strategic pivot to address the impact of GLP-1 drugs on the aesthetics market suggest management is taking steps to adapt. While the short-term financial outlook is challenging, these strategic adjustments and the reported improvement in Q4 same-store sales trends offer a glimmer of potential stabilization. An investor might 'hold' to observe if the new CFO and strategic initiatives can reverse the negative financial trajectory and capitalize on the evolving market landscape, rather than 'sell' immediately given the forward-looking strategic adjustments.

Keywords

AirSculpt Technologies, body contouring, aesthetics, Q3 2025 results, financial performance, revenue guidance, Adjusted EBITDA, CFO appointment, Michael Arthur, GLP-1 impact, minimally invasive procedures